View Item 

Show simple item record

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project
dc.contributor.authorDabaja, Bouthaina S.en_US
dc.contributor.authorVanderplas, Ann M.en_US
dc.contributor.authorCrosby‐thompson, Allison L.en_US
dc.contributor.authorAbel, Gregory A.en_US
dc.contributor.authorCzuczman, Myron S.en_US
dc.contributor.authorFriedberg, Jonathan W.en_US
dc.contributor.authorGordon, Leo I.en_US
dc.contributor.authorKaminski, Marken_US
dc.contributor.authorNiland, Joyceen_US
dc.contributor.authorMillenson, Michaelen_US
dc.contributor.authorNademanee, Auayporn P.en_US
dc.contributor.authorZelenetz, Andrewen_US
dc.contributor.authorLaCasce, Ann S.en_US
dc.contributor.authorRodriguez, Maria Almaen_US
dc.date.accessioned2015-04-02T15:12:32Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-04-01en_US
dc.identifier.citationDabaja, Bouthaina S.; Vanderplas, Ann M.; Crosby‐thompson, Allison L. ; Abel, Gregory A.; Czuczman, Myron S.; Friedberg, Jonathan W.; Gordon, Leo I.; Kaminski, Mark; Niland, Joyce; Millenson, Michael; Nademanee, Auayporn P.; Zelenetz, Andrew; LaCasce, Ann S.; Rodriguez, Maria Alma (2015). "Radiation for diffuse large Bâ cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project." Cancer 121(7): 1032-1039.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110862
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherradiationen_US
dc.subject.otherconsolidationen_US
dc.subject.otherearly stageen_US
dc.subject.otherrituximaben_US
dc.subject.othercyclophosphamideen_US
dc.subject.otherdoxorubicinen_US
dc.subject.othervincristineen_US
dc.subject.otherand prednisone (R‐CHOP)en_US
dc.titleRadiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes projecten_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110862/1/cncr29113.pdf
dc.identifier.doi10.1002/cncr.29113en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceAukema SM, Siebert R, Schuuring E, et al. Double‐hit B‐cell lymphomas. Blood. 2011; 117: 2319 ‐ 2331.en_US
dc.identifier.citedreferenceHans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275 ‐ 282.en_US
dc.identifier.citedreferenceMeyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B‐cell lymphoma treated with rituximab. J Clin Oncol. 2011; 29: 200 ‐ 207.en_US
dc.identifier.citedreferenceNyman H, Jerkeman M, Karjalainen‐Lindsberg ML, Banham AH, Leppa S. Prognostic impact of activated B‐cell focused classification in diffuse large B‐cell lymphoma patients treated with R‐CHOP. Mod Pathol. 2009; 22: 1094 ‐ 1101.en_US
dc.identifier.citedreferenceYang DH, Min JJ, Song HC, et al. Prognostic significance of interim (1)(8)F‐FDG PET/CT after three or four cycles of R‐CHOP chemotherapy in the treatment of diffuse large B‐cell lymphoma. Eur J Cancer. 2011; 47: 1312 ‐ 1318.en_US
dc.identifier.citedreferenceItti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F‐FDG PET in patients with diffuse large B‐cell lymphoma: SUV‐based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009; 50: 527 ‐ 533.en_US
dc.identifier.citedreferenceHaioun C, Itti E, Rahmouni A, et al. [18F]Fluoro‐2‐deoxy‐D‐glucose positron emission tomography (FDG‐PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106: 1376 ‐ 1381.en_US
dc.identifier.citedreferenceMikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG‐PET after two to three cycles of chemotherapy predicts progression‐free and overall survival in high‐grade non‐Hodgkin lymphoma. Ann Oncol. 2005; 16: 1514 ‐ 1523.en_US
dc.identifier.citedreferenceKostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006; 107: 2678 ‐ 2687.en_US
dc.identifier.citedreferenceReyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005; 352: 1197 ‐ 1205.en_US
dc.identifier.citedreferencePfreundschuh M, Ho AD, Cavallin‐Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good‐prognosis diffuse large‐B‐cell lymphoma treated with CHOP‐like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008; 9: 435 ‐ 444.en_US
dc.identifier.citedreferenceMiller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate‐ and high‐grade non‐Hodgkin's lymphoma. N Engl J Med. 1998; 339: 21 ‐ 26.en_US
dc.identifier.citedreferenceHorning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited‐stage diffuse aggressive non‐Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004; 22: 3032 ‐ 3038.en_US
dc.identifier.citedreferenceBonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25: 787 ‐ 792.en_US
dc.identifier.citedreferenceKahl BS. Bulky aggressive B‐cell lymphoma: to radiate or not to radiate—that is the question. J Clin Oncol. 2014; 32: 1097 ‐ 1098.en_US
dc.identifier.citedreferenceCoiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma. N Engl J Med. 2002; 346: 235 ‐ 242.en_US
dc.identifier.citedreferenceSafar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B‐cell lymphoma treated with anthracycline‐based chemotherapy plus rituximab. J Clin Oncol. 2012; 30: 184 ‐ 190.en_US
dc.identifier.citedreferenceAlizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B‐cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503 ‐ 511.en_US
dc.identifier.citedreferenceBucci MK. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non‐Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. http://onco link.org/conferences/article.cfm?id=5140. Accessed September 2014.en_US
dc.identifier.citedreferenceHeld G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B‐cell lymphoma. J Clin Oncol. 2014; 32: 1112 ‐ 1118.en_US
dc.identifier.citedreferencePhan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B‐cell lymphoma treated with R‐CHOP chemotherapy. J Clin Oncol. 2010; 28: 4170 ‐ 4176.en_US
dc.identifier.citedreferenceMarcheselli L, Marcheselli R, Bari A, et al. Radiation therapy improves treatment outcome in patients with diffuse large B‐cell lymphoma. Leuk Lymphoma. 2011; 52: 1867 ‐ 1872.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29113.pdf
Size:
143.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.